Contemporary management of ST-segment elevation myocardial infarction
Ajay Yadlapati1, Mark Gajjar1, Daniel R Schimmel1
1Division of Cardiology, Bluhm Cardiovascular Institute, Feinberg School of Medicine, Northwestern University, 676 N. St. Clair Street, Suite 600, Chicago, IL, 60611-2996, USA.
Insights
Prompt recognition and updated treatment protocols are crucial for ST-elevation myocardial infarction (STEMI). Focusing on total pain-to-balloon time and early P2Y12 inhibitor use improves outcomes for acute myocardial infarction (AMI) patients.
Area of Science:
- Cardiology
- Emergency Medicine
Background:
- ST-elevation myocardial infarction (STEMI) accounts for 25-40% of acute myocardial infarction (AMI) cases.
- Significant advancements in STEMI care have emerged since the 2013 guidelines.
- Optimizing treatment and transport algorithms is essential, especially for patients treated at non-primary percutaneous coronary intervention (PCI) centers.
Purpose of the Study:
- To review recent advancements and data impacting optimal STEMI management.
- To emphasize the importance of reducing total pain-to-balloon (P2B) times.
- To highlight new therapeutic strategies and technological innovations in STEMI care.
Main Methods:
- Review of recent clinical data and practice guidelines related to STEMI.
- Analysis of treatment advancements, including pharmacotherapy and transport logistics.
- Exploration of emerging technologies and investigational therapies for STEMI.
Main Results:
- Improved patient outcomes are associated with reduced P2B times and optimized transport.
- Early administration of oral P2Y12 inhibitors, including crushed forms, enhances treatment efficacy.
- Avoiding concurrent morphine use with P2Y12 inhibitors is recommended.
- Novel therapies like Bioresorbable Vascular Scaffolds and ultrasound-guided microbubbles show future promise.
Conclusions:
- Prompt recognition of STEMI at both patient and healthcare system levels remains paramount.
- Integrating new data on P2B times, P2Y12 inhibitor administration, and drug interactions refines STEMI protocols.
- Technological innovations offer potential future improvements in STEMI management.
Abstract:
ST-elevation myocardial infarction (STEMI), which constitutes nearly 25-40 % of current acute myocardial infarction (AMI) cases, is a medical emergency that requires prompt recognition and treatment. Since the 2013 STEMI practice guidelines, a wealth of additional data that may further advance optimal STEMI practices has emerged. These data highlight the importance of improving patient treatment and transport algorithms for STEMI from non-primary percutaneous coronary intervention (PCI) centers. In addition, a focus on the reduction of total pain-to-balloon (P2B) times rather than simply door-to-balloon (D2B) times may further improve outcomes after primary PCI for STEMI. The early administration of newer oral P2Y12 inhibitors, including crushed forms of these agents for faster absorption, represents another treatment advancement. Recent data also suggest avoiding concurrent morphine use due to interactions with P2Y12 inhibitors. Furthermore, new technological advancements and investigational therapies, including Bioresorbable Vascular Scaffolds and the use of pre-intervention intravenous microbubbles with transthoracic ultrasound, hold promise to play a useful role in future STEMI care. Despite these advancements, the prompt recognition of STEMI, at both the patient and health care system level, remains the cornerstone of optimal treatment.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:26Angina IV: Management
01:14Myocarditis III: Medical Management
01:26Acute Coronary Syndrome V: Nursing Management
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations